“This technology allows us to look inside the brain, evaluate blood flow characteristics and track emboli in patients. It provides us with critical information on brain health in real-time to help us diagnose neurological disorders, prior to the need for additional, more invasive testing,” said Prof. Claudio Baracchini, Director of the Stroke Unit and Neurosonology Lab at the University of Padua (Italy) and President of the European Society of Neurosonology and Cerebral Hemodynamics (ESNCH).
Neural Analytics have presented research data that demonstrated there was no statistical difference between ultrasound blood flow data collected with the NeuralBot System and data collected manually by an expert technician with using traditional ultrasound platform.
“We are committed to advancing brain healthcare through transformative technology that empowers neurologists with the critical information needed to make clinical decisions and improve patient outcomes,” said Dr Leo Petrossian, Co-Founder and Chief Executive Officer of Neural Analytics. “Our products provide clinicians with a cost effective and non-invasive assessment of a patient’s brain health, and can help clinicians diagnose brain disorders, potentially without the need for more invasive testing.”
The worldwide prevalence of stroke in 2010 was 33 million cases, with 16.9 million people having their first stroke. Stroke claims a life every five seconds and is the second most common cause of death accounting for over 11.9 percent total deaths worldwide The burden of disease caused by stroke is set to double worldwide by 2030. The number of stroke events in Europe is projected to rise from 1.1 million to 1.5 million per year by 2025. Stroke is a time sensitive disease and requires intervention within 24 hours of onset of symptoms. Incorrect assessment of large vessel stroke leads to misdiagnosis and treatment delays, resulting in death or disability for stroke patients. Despite recent advances in life-saving treatments for acute ischemic stroke, fewer than five percent of stroke patients qualify for intervention because they do not present early enough.
The NeuralBot System with the Lucid M1 TCD System is approved in Europe as the ‘Lucid™ Robotic System’ and has also received 510(k) clearance from the Food and Drug Administration.
Los Angeles, CA , USA